The current study differs from the study by Wong et al
These rapid mood fluctuations, particularly the emergence or intensification of depressive and anxious states, can significantly disrupt daily functioning and interactions with others, severely impacting an individual's overall well-being
Accordingly, we encourage the adoption of GLP-1RA plus SGLT2i combination therapy in patients with T2DM and established atherosclerotic cardiovascular disease (ASCVD) or multiple risk factors for ASCVD (i.e., age 55 years, overweight/obesity, dyslipidemia, hypertension, current tobacco use, left ventricular hypertrophy, and/or proteinuria)
This approach helps reduce nausea, especially during the first 4-5 weeks of treatment or after any dose adjustments
N-Acetylcysteine is also a subcomponent of glutathione, but it is not naturally produced by our livers
When the disease develops into cirrhosis, it is difficult to reverse the patients condition with conventional clinical treatments